Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study

Fig. 2

Tumor response and survival outcomes. a Waterfall plot of the best percentage change in target lesion size from baseline according to RECIST 1.1; (b) Waterfall plot of the best percentage change in target lesion size from baseline according to mRECIST; (c) Kaplan–Meier curves of progression-free survival; (d) Kaplan–Meier curves of overall survival. RECIST Response Evaluation Criteria in Solid Tumors, mRECIST Modified Response Evaluation Criteria in Solid Tumors, CR complete response, PR partial response, SD stable disease, PD progressive disease, Mo months

Back to article page